Cargando…

Efficacy and safety of activated prothrombin complex concentrate for the reversal of vitamin K antagonist major bleeding

Data on the use of activated prothrombin complex concentrate (aPCC) for the management of warfarin associated major bleeding is sparse. The objective of the study was to assess the achievement of effective clinical hemostasis using aPCC in patients presenting with major bleeding while on warfarin. W...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sheikh-Taha, Marwan, Crawley, R. Monroe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810750/ https://www.ncbi.nlm.nih.gov/pubmed/35110612 http://dx.doi.org/10.1038/s41598-022-05803-w

Ejemplares similares

Prothrombin complex concentrate in surgical patients: retrospective evaluation of vitamin K antagonist reversal and treatment of severe bleeding
por: Schick, Kerstin S, et al.
Publicado: (2009)

Safety and efficacy of a strategy of vitamin K antagonist reversal with prothrombin complex concentrates compared to vitamin K in patients with hip fracture
por: Jay-Caillierez, Lucille, et al.
Publicado: (2021)

Reversal of Vitamin K Antagonist Therapy by Prothrombin Complex Concentrate before Thrombolysis for Acute Stroke
por: Chausson, Nicolas, et al.
Publicado: (2013)

Clinical outcome of patients with a vitamin K antagonist‐associated bleeding treated with prothrombin complex concentrate
por: Brekelmans, Marjolein P. A., et al.
Publicado: (2017)

Use of Prothrombin Complex Concentrate for Vitamin K Antagonist Reversal before Surgical Treatment of Intracranial Hemorrhage
por: Wong, Yun
Publicado: (2011)

Optimal Dosage and Administration Practices for Vitamin K Antagonist Reversal With 4-Factor Prothrombin Complex Concentrate
por: Rhoney, Denise H., et al.
Publicado: (2020)

Benefits and harms of 4-factor prothrombin complex concentrate for reversal of vitamin K antagonist associated bleeding: a systematic review and meta-analysis
por: Brekelmans, Marjolein P. A., et al.
Publicado: (2017)

Increased risk of volume overload with plasma compared with four‐factor prothrombin complex concentrate for urgent vitamin K antagonist reversal
por: Refaai, Majed A., et al.
Publicado: (2015)

Guideline-concordant administration of prothrombin complex concentrate and vitamin K is associated with decreased mortality in patients with severe bleeding under vitamin K antagonist treatment (EPAHK study)
por: Tazarourte, Karim, et al.
Publicado: (2014)

Safety of a Four‐factor Prothrombin Complex Concentrate Versus Plasma for Vitamin K Antagonist Reversal: An Integrated Analysis of Two Phase IIIb Clinical Trials
por: Milling, Truman J., et al.
Publicado: (2016)

Application of prothrombin complex concentrate for reversal of direct oral anticoagulants in clinical practice: indications, patient characteristics and clinical outcomes compared to reversal of vitamin K antagonists
por: Müller, Martin, et al.
Publicado: (2019)

Prothrombin complex concentrate in the management of major bleeding induced by oral anticoagulant therapy
por: AlSheef, Mohammed, et al.
Publicado: (2022)

Acquired deficiency of prothrombin complex coagulation factors in major bleeding is a therapeutic indication of 4‐factor prothrombin complex concentrates
por: Wiedermann, Christian J.
Publicado: (2020)

Reversal of Vitamin K Antagonist (VKA) effect in patients with severe bleeding: a French multicenter observational study (Optiplex) assessing the use of Prothrombin Complex Concentrate (PCC) in current clinical practice
por: Desmettre, Thibaut, et al.
Publicado: (2012)

Three- versus four-factor prothrombin complex concentrate for the reversal of warfarin-induced bleeding
por: Holt, Tara, et al.
Publicado: (2018)

Coagulation Factor Plasma Levels Following Administration of a 4-Factor Prothrombin Complex Concentrate for Rapid Vitamin K Antagonist Reversal in Japanese Patients
por: Yasaka, Masahiro, et al.
Publicado: (2018)

Thromboembolic Events After Vitamin K Antagonist Reversal With 4-Factor Prothrombin Complex Concentrate: Exploratory Analyses of Two Randomized, Plasma-Controlled Studies
por: Milling, Truman J., et al.
Publicado: (2015)

3-Factor versus 4-Factor Prothrombin Complex Concentrates for the Reversal of Vitamin K Antagonist-Associated Coagulopathy: A Systematic Review and Meta-analysis
por: Puchstein, Dorothea, et al.
Publicado: (2023)

Randomised controlled trial protocol to evaluate a fixed dose prothrombin complex concentrate against the variable dose in vitamin K antagonist related bleeding (PROPER3)
por: Abdoellakhan, Rahat A, et al.
Publicado: (2018)

Prothrombin complex concentrates in warfarin anticoagulation reversal
por: Costa-Lima, Carolina, et al.
Publicado: (2012)

Prothrombin complex concentrate use in surgical patients: a retrospective analysis of efficacy and safety for coumarin reversal and bleeding management
por: Schick, KS, et al.
Publicado: (2008)

Fixed Versus Variable Dosing of Prothrombin Complex Concentrate in Vitamin K Antagonist-Related Intracranial Hemorrhage: A Retrospective Analysis
por: Abdoellakhan, Rahat Amadkhan, et al.
Publicado: (2016)

Reversal of oral anticoagulation with prothrombin complex concentrate (Octaplex)
por: Riess, H, et al.
Publicado: (2007)

Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery
por: Cappabianca, Giangiuseppe, et al.
Publicado: (2016)

Four-Factor Prothrombin Complex Concentrate Reduces Time to Procedure in Vitamin K Antagonist-Treated Patients Experiencing Gastrointestinal Bleeding: A Post Hoc Analysis of Two Randomized Controlled Trials
por: Refaai, Majed A., et al.
Publicado: (2017)

Four‐factor prothrombin complex concentrate reverses apixaban‐associated bleeding in a rabbit model of acute hemorrhage
por: Herzog, E., et al.
Publicado: (2015)

Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding
por: Rech, Megan A., et al.
Publicado: (2021)

The role of prothrombin complex concentrates in reversal of target specific anticoagulants
por: Babilonia, Katrina, et al.
Publicado: (2014)

Four-factor prothrombin complex concentrate (Beriplex® P/N) is superior to three-factor prothrombin complex concentrate for reversal of coumarin anticoagulation
por: Herzog, E, et al.
Publicado: (2015)

Comparison of bleeding risk scores and evaluation of major bleeding predictive factors in patients with major bleeding due to vitamin K antagonist use
por: Yildirim, Sinan, et al.
Publicado: (2023)

Emergency Management of Major Bleeding in a Case of Maxillofacial Trauma and Anticoagulation: Utility of Prothrombin Complex Concentrates in the Shock Room
por: Morotti, Alessandro, et al.
Publicado: (2015)

A meta‐analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor–related major bleeding
por: Jaspers, Tessa, et al.
Publicado: (2021)

Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation
por: Grottke, Oliver, et al.
Publicado: (2016)

Clinical review: Prothrombin complex concentrates - evaluation of safety and thrombogenicity
por: Sørensen, Benny, et al.
Publicado: (2011)

BLEEDING TENDENCY AND PROTHROMBIN DEFICIENCY IN BILIARY FISTULA DOGS: EFFECT OF FEEDING BILE AND VITAMIN K
por: Smith, H. P., et al.
Publicado: (1938)

Four-factor prothrombin complex concentrate (Beriplex® P/N) mediated reversal of apixaban-induced bleeding in a rabbit model
por: Herzog, E, et al.
Publicado: (2015)

The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review
por: Hoffman, Maureane, et al.
Publicado: (2018)

Effectiveness of prothrombin complex concentrate for the treatment of bleeding: A systematic review and meta‐analysis
por: van den Brink, Daan P., et al.
Publicado: (2020)

Prothrombin Complex Concentrate for Rapid Reversal of Warfarin Anticoagulation to Allow Neuraxial Blockade
por: Skerritt, Conor, et al.
Publicado: (2014)

Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors
por: Tao, Jing, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1ro5aqgg4fdqrla03mmmtkrm3m